Abstract
Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi and several opportunistic molds and yeasts. In all instances, the voriconazole MICs were lower than those of fluconazole. In most instances, the MICs were lower than the recorded MICs of amphotericin B and itraconazole.
Full Text
The Full Text of this article is available as a PDF (146.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry A. L., Brown S. D. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother. 1996 Aug;40(8):1948–1949. doi: 10.1128/aac.40.8.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- George D., Miniter P., Andriole V. T. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 1996 Jan;40(1):86–91. doi: 10.1128/aac.40.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Martin M. V., Yates J., Hitchcock C. A. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother. 1997 Jan;41(1):13–16. doi: 10.1128/aac.41.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Murphy M., Bernard E. M., Ishimaru T., Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 1997 Mar;41(3):696–698. doi: 10.1128/aac.41.3.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Radford S. A., Johnson E. M., Warnock D. W. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997 Apr;41(4):841–843. doi: 10.1128/aac.41.4.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rex J. H., Pfaller M. A., Galgiani J. N., Bartlett M. S., Espinel-Ingroff A., Ghannoum M. A., Lancaster M., Odds F. C., Rinaldi M. G., Walsh T. J. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997 Feb;24(2):235–247. doi: 10.1093/clinids/24.2.235. [DOI] [PubMed] [Google Scholar]